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Context: There is little information on the potential impact of serum 1,25-dihydroxyvitamin D
[1,25(OH)2D] on bone health including turnover.
Objective: The objective of the study was to determine the influence of 1,25(OH)2D and 25-hy-
droxyvitamin D [25(OH)D] on bone health in middle-aged and older European men.
Design, Setting, and Participants:Men aged 40–79 years were recruited frompopulation registers
in 8 European centers. Subjects completed questionnaires that included questions concerning
lifestyle and were invited to attend for quantitative ultrasound (QUS) of the heel, assessment of
height and weight, and a fasting blood sample from which 1,25(OH)2D, 25(OH)D, and PTH were
measured. 1,25(OH)2D was measured using liquid chromatography tandem mass spectrometry.
Bone markers serum N-terminal propeptide of type 1 procollagen (P1NP) and crosslinks (-cTX)
were also measured. Dual-energy x-ray absorptiometry (DXA) of the hip and lumbar spine was
performed in 2 centers.
MainOutcomeMeasure(s):QUSof theheel, bonemarkers P1NPand-cTX, andDXAof thehip and
lumbar spine were measured.
Results: A total of 2783 men, mean age 60.0 years (SD 11.0) were included in the analysis. After
adjustment for age and center, 1,25(OH)2D was positively associated with 25(OH)D but not with
PTH. 25(OH)D was negatively associated with PTH. After adjustment for age, center, height,
weight, lifestyle factors, and season, 1,25(OH)2D was associated negatively with QUS and DXA
parameters and associated positively with -cTX. 1,25(OH)2D was not correlated with P1NP.
25(OH)Dwaspositivelyassociatedwith theQUSandDXAparametersbutnot related toeitherbone
turnover marker. Subjects with both high 1,25(OH)2D (upper tertile) and low 25(OH)D (lower
tertile) had the lowest QUS and DXA parameters and the highest -cTX levels.
Conclusions: Serum 1,25(OH)2D is associated with higher bone turnover and poorer bone health
despite being positively related to 25(OH)D. A combination of high 1,25(OH)2D and low 25(OH)D
is associated with the poorest bone health. (J Clin Endocrinol Metab 98: 995–1005, 2013)
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Abbreviations: BMDa, areal bone mineral density; BMI, body mass index; BUA, broadband
ultrasound attenuation; CI, confidence interval; -cTX, -C-terminal cross-linked telopep-
tide; CV, coefficient of variation; DXA, dual-energy x-ray absorptiometry; E2, estradiol;
EMAS, European Male Aging Study; LC-MS/MS, liquid chromatography-tandemMS; MS,
mass spectrometry; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin
D; PASE, Physical Activity Scale for the Elderly; P1NP, N-terminal propeptide of type 1
procollagen; QUS, quantitative ultrasound; SOS, speed of sound; T, testosterone.
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Vitamin D deficiency is common, particularly amongthe elderly (1). Vitamin D status is most commonly
characterized by measuring serum 25-hydroxyvitamin D
[25(OH)D], the most abundant circulating metabolite.
The influence of 25(OH)D on bone health has been ex-
tensively examined (1), particularly in postmenopausal
women, with fewer studies in men (2–11).
1,25-Dihydroxyvitamin D [1,25(OH)2D] is the meta-
bolically active molecule responsible for most of the ac-
tions of vitamin D and is derived from 25(OH)D by 1-
hydroxylation primarily in the kidney (12). The main
effect of 1,25(OH)2D is to increase calcium absorption
from the gut (13). 1,25(OH)2D binds to the vitamin D
receptor in the epithelial cells of the duodenum causing the
synthesis of calcium binding proteins that regulate active
intestinal calcium absorption (13, 14). It also stimulates
calcium reabsorption in the kidney. The production of
1,25(OH)2D is stimulated by PTH and its concentrations
directly influenced by serum calcium and phosphate (15).
In addition to regulating serum calcium uptake in the in-
testine and kidney, evidence from in vitro and animal stud-
ies suggest that 1,25(OH)2D may also regulate calcium
resorption from bone by having direct effects on bone cells
(13, 14, 16). There is, however, little information on the
potential impact of serum 1,25(OH)2D on bone health
including turnover.
Compared with 25(OH)D, serum concentrations of
1,25(OH)2D are 1000-fold lower and its half-life much
shorter at approximately 7 hours (12). Measurement of
1,25(OH)2D has typically been by RIA, often preceded by
HPLC, thus making it time consuming. Such measurement
also typically required large volumes of serum. Recent ad-
vances in mass spectrometry (MS) have provided more
accurate measurements of many metabolic hormones, but
to date very few MS-based assays for 1,25(OH)2D have
been developed. Consequently, epidemiological data are
scarce, but there is some evidence that 1,25(OH)2D de-
clines with age in some (17–19) but not all studies (20, 21).
Among the few studies that have measured both vitamin
D metabolites and also PTH, some provide evidence of a
positive association between 1,25(OH)2D and 25(OH)D
(17–19) and between 1,25(OH)2D and PTH (17, 18).
There are very few studies examining the influence of
1,25(OH)2D on bone health, and the data are conflicting.
A small study of healthy men aged 30–92 years found no
association between 1,25(OH)2D and radial or vertebral
bone mineral content (21). One study showed a doubling
of the risk of hip fracture in postmenopausal women with
low serum 1,25(OH)2D (22), and another study found
lower 1,25(OH)2D levels in hip fracture patients com-
pared with controls (23).
The European Male Aging Study (EMAS) is a large
population-based study of aging in middle-aged and older
European men, which incorporates an extensive range of
clinical, biochemical, health, and lifestyle information, in-
cluding a new state-of-the-art MS-based measurement of
serum 1,25(OH)2D. We used data from EMAS to examine
the interrelationships between 1,25(OH)2D, 25(OH)D,
and PTH. We compared the influence of 1,25(OH)2D,
25(OH)D, and PTH on bone health measured using quan-
titative ultrasound (QUS) of the heel, dual-energy x-ray
absorptiometry (DXA) of the hip and lumbar spine, and
serum markers of bone turnover.
Materials and Methods
Subjects
The subjects included in this analysis were recruited for par-
ticipation in EMAS. Details concerning the study design and
recruitment have been described previously (24). Briefly, men
were recruited from population-based sampling frames in 8 cen-
ters: Florence (Italy), Leuven (Belgium), Ło´dz´ (Poland), Malmo¨
(Sweden), Manchester (United Kingdom), Santiago de Compos-
tela (Spain), Szeged (Hungary), and Tartu (Estonia). Stratified
random sampling was used with the aim of recruiting equal num-
bers of men in each of 4 10-year age bands: 40–49, 50–59,
60–69, and 70–79 years. Subjects were invited by letter to com-
plete a postal questionnaire and attend for an interviewer-as-
sisted questionnaire, clinical assessments and a fasting blood
sample. The overall response rate was 45%. Ethical approval for
the study was obtained in accordance with local institutional
requirements in each center. All subjects provided written in-
formed consent.
Departments of Andrology and Endocrinology (D.V.) and Laboratory Medicine (D.V., I.J., J.B.), Leuven University Division of Geriatric Medicine and Centre for Metabolic Bone Diseases
(E.G.,M.L., S.B.), and LeuvenUniversity Laboratory ofMolecular Endocrinology (M.L., F.C.), Department ofMolecular Cell Biology, KatholiekeUniversiteit Leuven, B-3001 Leuven, Belgium;
Arthritis Research UK Epidemiology Unit (S.R.P., T.W.O., D.M.L.), Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PT, United Kingdom;
Radiology and Manchester Academic Health Science Centre (J.E.A.) and Andrology Research Unit (J.D.F., F.C.W.W.), Developmental and Regenerative Biomedicine Research Group, The
University ofManchester,Manchester Academic Health Science Centre, The Royal Infirmary,Manchester, United Kingdom;Medical Research Council HumanNutrition Research (K.A.W.),
Elsie Widdowson Laboratory, Cambridge CB1 9NL, United Kingdom; Department of Obstetrics, Gynaecology, and Andrology (G.B.), Albert Szent-Gyorgy Medical University, H-6721
Szeged, Hungary; Department of Medicine (F.F.C.), Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago, 15705 Santiago de Compostela, Spain; Centro
de Investigacio´n Biome´dica en Red de Fisiopatologia Obesidad y Nutricion (CB06/03), Instituto Salud Carlos III, Santiago deCompostela, 28029Madrid, Spain;Manchester Royal Infirmary,
Manchester M13 9WL, United Kingdom; Andrology Unit (GF.), Department of Clinical Physiopathology, University of Florence, 50121 Florence, Italy; Scanian Andrology Centre (A.G.),
Department of Urology,Malmo¨ University Hospital, University of Lund, SE-22 184 Lund, Sweden; Department of Endocrinology (T.S.H.), Royal Free andUniversity CollegeHospitalMedical
School, Royal Free Hospital, Hampstead, London NW3 2Q United Kingdom; Department of Surgery and Cancer (I.T.H.), Imperial College London, Hammersmith Campus, London W12
ONN, United Kingdom; Department of Andrology and Reproductive Endocrinology (K.K.), Medical University of Lodz, 90-419 Lodz, Poland; Department of Human Nutrition (M.E.J.L.),
University of Glasgow, Glasgow G12 8TA, Scotland, United Kingdom; School of Community-Based Medicine (N.P.), The University of Manchester, Salford Royal National Health Service
Trust, Salford M6 8HD, United Kingdom; and Andrology Unit (M.P.), United Laboratories of Tartu University Clinics, 50090 Tartu, Estonia
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Study questionnaires and clinical data
The postal questionnaire included questions concerning cur-
rent smoking, alcohol consumption in the previous year (re-
sponse set  every day/5–6 days per week/3–4 days per week/
1–2 days per week/less than once a week/not at all) and also
whether they were currently being treated for a range of medical
conditions, which included diabetes and prostate disease. The
interviewer assisted questionnaire included the Physical Activity
Scale for the Elderly (PASE) and also asked about current med-
ications (25). Subjects also completed the Reubens physical per-
formance test (26). Height was measured to the nearest 1 mm
using a stadiometer (Leicester height measure, SECA UK Ltd,
Birmingham, United Kingdom) and body weight to the nearest
0.1 kg using an electronic scale (SECA model number
8801321009; SECA UK Ltd). A single fasting morning (before
1000 hours) venous blood sample was obtained from all
subjects.
Assessment of 25(OH)D and 1,25(OH)2D3
Serum 25(OH)D levels were determined using a RIA (RIA kit;
DiaSorin, Stillwater, Minnesota). Intra- and interassay coeffi-
cients of variation (CVs) for 25(OH)D were 11% and 8%, re-
spectively. The detection limit of the RIA kit was 2.0 ng/mL.
1,25-(OH)2D3 was measured by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) as a lithium adduct according to
the method described by Casetta et al (27). In contrast to this
earlier method, methanol instead of acetonitrile was used for
protein precipitation of 200 L serum samples. The injected
volume of supernatant was increased from 90 L to 180 L and
injected on a Shimadzu Prominence HPLC Shimadzu, Kyoto,
Japan) (coupled to an AB Sciex API 5500 QTRAP tandem mass
spectrometer (Sciex, Warrington, United Kingdom). The use of
ultrapure methanol (Fisher; Optima liquid chromatography-
mass spectrometry) further helped to increase sensitivity due to
reduced ion suppression in the LC-MS/MS interface (28). The
1,25-(OH)2D3 standard dissolved in ethanol was calibrated by
measuring the UV absorbance at 264 nm, using a molar absor-
bance of 18 300. Calibrators (6.25–250 pg/mL) were dissolved
in a surrogate matrix containing bovine serum albumin (60 g/L)
dissolved in physiological water with the addition of 0.2% serum
with a 1,25-(OH)2D3 concentration lower than 10 pg/mL. The
internal standard peak area of calibrators or serum samples did
not fluctuate more than 20% relative to a water blank. Calibra-
tion curves were linear through zero over the entire measuring
range from 6.25 to 250 pg/mL. The signal to noise ratio of a 6.25
pg/mL calibrator was greater than 10, allowing the definition of
a limit of quantification of less than 6.25 pg/mL. Carryover as
measured in a blank after the injection of the highest calibrator
level was lower than the limit of detection, the latter defined as
3 times the background noise level. Potential interferences from
24(R),25(OH)2D3 and 25(S),26(OH)2D3 but not 1,25(OH)2-3-
epi-D3 were chromatographically resolved from the 1,25(OH)2D3
peak. The interday imprecision of pooled serum at high and low
serum concentrations were, respectively, 10.1% CV (n 9) for
serum, with a mean concentration of 7.16 pg/mL, and 5.9% CV
(n  20) for serum, with a mean concentration of 55.8 pg/mL.
Seventy-six samples were measured with both this new LC-
MS/MS method and the traditional liquid chromatography-RIA
method as described by Bouillon et al (29), which resulted in a
linear fit of 1.84  1.006x as well as an excellent coefficient of
correlation of r  0.91.
Hormone measurements
Measurements of testosterone (T) and estradiol (E2) were
carried out by gas chromatography mass spectrometry. SHBG
was measured by the Modular E170 platform electrochemilu-
minescence immunoassay (Roche Diagnostics, Mannheim, Ger-
many). The free and bioavailable (non-SHBG bound) T and E2
levels were derived from total hormone, SHBG, and albumin
concentrations using mass action equations and association con-
stants. Further details are described elsewhere (30). In addition,
samples were transported in frozen state to a single laboratory
for measurement of PTH and IGF-I (University of Santiago de
Compostela). Serum was assayed for PTH using a chemilumi-
nescence immunoassay (Nichols Advantage Bio-Intact PTH as-
say; Quest Diagnostics, Madison, New Jersey). Interassay CV for
PTH was 2.8%. The detection limit of the chemiluminescence
immunoassay was 1.6 pg/mL. Serum was assayed for IGF-I using
chemiluminescence as previously described (31).
QUS of the heel
QUS of the left heel was performed with the Sahara clinical
sonometer (Hologic, Inc, Waltham, Massachusetts) using a stan-
dardized protocol in all centers. Outputs included broadband
ultrasound attenuation (BUA; measured in decibels per mega-
hertz) and speed of sound (SOS; measured in meters per second).
The in vivo CVs were 2.8% and 0.3% for BUA and SOS, re-
spectively. Repeat measurements were performed on a roving
phantom at each of the 8 centers (32). Standardized CVs for
within-machine variability ranged by center: for SOS, from 1.0%
to 5.6%, and BUA from 0.7% to 2.7%. Standardized CVs for
between-machine variability were 4.8% for BUA and 9.7% for
SOS (32).
Dual-energy x-ray absorptiometry
Areal bone mineral density (BMDa) scans were carried out in
the Manchester and Leuven subsets of EMAS (n  676). Both
sites used DXA QDR 4500A devices from the same manufac-
turer (Hologic, Inc). BMDa was measured at the lumbar spine
(L1 to L4) and proximal femur (total region). The precision er-
rors in Leuven were 0.57% and 0.56% at the lumbar spine and
total femur region, respectively. In Manchester, these precision
errors were 0.97% and 0.97%, respectively. Both devices were
cross-calibrated with the European spine phantom (33).
Bone marker measurements
To assess bone resorption, serum -C-terminal cross-linked
telopeptide (-cTX) was measured on the Elecsys 2010 auto-
mated analyzer (Roche Diagnostics GmbH) as previously de-
scribed (34). The intraassay CV evaluated by repeated measure-
ments of several serum samples was less than 5.0%. The
detection limit was 10 pg/mL. To evaluate bone formation, mea-
surements were performed on the Elecsys 2010 with a 2-site
assay using monoclonal antibodies raised against intact human
N-terminal propeptide of type 1 procollagen (P1NP) purified
from human amniotic fluid. The interassay CV was less than
3.0% and the lower detection limit less than 5 ng/mL.
Analysis
The association between 1,25(OH)2D and 25(OH)D as well
as 1,25(OH)2D, 25(OH)D, and PTH was initially assessed vi-
sually using scatter plots and superimposing linear lines and lo-
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cally weighted scatter plot smooth curves. The strength of the
associations was then determined using linear regression after
adjusting for age and center. For ease of interpretation and com-
parison, 1,25(OH)2D, 25(OH)D, and PTH were standardized
into Z scores (per SD). These variables were also categorized into
quintiles to assess the potential threshold effects.
The association between 1,25(OH)2D, 25(OH)D, PTH, and
factors that could potentially confound associations with bone
parameters were assessed using linear regression adjusting for
age and center. These factors included height (centimeters),
weight (kilograms), body mass index (BMI) (kilograms per
square meter), PASE score (per 100), time to walk 50 feet (sec-
onds), smoking (percentage), alcohol consumption (categorized
by number of days consumed alcohol), and, after standardizing
to Z scores, serum calcium, creatinine, total and free T, total and
free E2, SHBG, and IGF-I. Multivariable linear regression was
then used to determine the association between 1,25(OH)2D,
25(OH)D, PTH, and QUS parameters (BUA and SOS), DXA
(total hip and lumbar spine), and bone turnover parameters
(PINP and -cTX) with the bone measures as dependent vari-
ables, adjusting for age, center, season of measurement, and fac-
tors found to be associated with the bone outcomes in the pre-
vious analysis. All continuous variables were standardized into
Z scores (per SD).
To assess the influence of the combination of 1,25(OH)2D
and 25(OH)D on bone health, subjects were categorized into 4
groups: 1, normal 25(OH)D and 1,25(OH)2D; 2, normal
25(OH)D and high 1,25(OH)2D; 3, low 25(OH)D and normal
1,25(OH)2D; and 4, low 25(OH)D and high 1,25(OH)2D. Low
25(OH)D was determined as those in the lowest tertile of
25(OH)D (17.7 ng/mL) and high 1,25(OH)2D was determined
as those in the highest tertile of 1,25(OH)2D (64.6 pg/mL).
Tertiles were chosen because it provided greater statistical power
than quintiles, although broadly similar results were obtained
when subjects were categorized using quintiles. A similar cate-
gorization was used to assess the combination of low 25(OH)D
and high PTH. These models included age, center, season of
measurement, and factors found to be associated with the bone
outcomes. Results of all linear regression analyses are expressed
as standardized -coefficients and 95% confidence intervals
(CIs). Statistical analysis was performed using STATA version
9.2 (http://www.stata.com).
Results
Subjects
A total of 2783 men with a mean age of 60.0 years (SD
11.0) had complete 1,25(OH)2D, 25(OH)D, QUS, and
bone marker data. Characteristics of the subjects are
shown in Table 1. Mean BMI was 27.6 kg/m2. A little more
than one fifth of the subjects reported that they currently
smoke, whereas 56% of the men reported consuming al-
cohol on at least 1 day per week, 4% reported currently
taking corticosteroids, and 0.6% was on calcium and/or
vitamin D supplementation. Mean 1,25(OH)2D was 59.3
pg/mL (SD 16.5), 25(OH)D 24.4 ng/mL (SD 12.4), and
PTH 28.4 pg/mL (SD 12.1). As expected, there was some
variation in 1,25(OH)2D and 25(OH)D levels according
to the season in which they were measured (Fig. 1). The
highest 25(OH)D was observed in the summer and au-
tumn (mean 29.6 and 29.9 ng/mL, respectively) and the
lowest in the winter and spring months (mean 20.9 and
20.4 ng/mL, respectively). Levels of 1,25(OH)2D followed
a similar pattern. In addition, there was significant vari-
ation in 1,25(OH)2D, 25(OH)D, and PTH by center (Sup-
plemental Table 1, published on The Endocrine Society’s
Journals Online web site at http://jcem.endojournals.org);
however, there did not appear to be any trend toward
decreasing levels 25(OH)D with increasing latitude.
Association between 1,25(OH)2D, 25(OH)D, and PTH
1,25(OH)2D was positively correlated with 25(OH)D
(-coefficient  0.457 pg/mL; P  .001) (Fig. 2A). The
association persisted after adjustment for age and center,
and there was no evidence of threshold effects when
25(OH)D was categorized into quintiles or an interaction
with PTH when PTH was categorized into quintiles (data
not shown). There was a modest correlation between
1,25(OH)2D and PTH (.060 pg/mL; P .021) (Fig.
2B), which was attenuated after adjustment for age and
center. 25(OH)D was negatively associated with PTH
(.194 ng/mL; P .001) (Fig. 2C). This relationship
Table 1. Subject Characteristics
Variable
Subjects (n  2783)
Mean (SD) Range
Age at interview, y 60.0 (11.0) 40.1–82.7
Height, cm 173.5 (7.4) 147.0–199.5
Weight, kg 83.3 (13.8) 43.0–175.0
BMI, kg/m2 27.6 (4.0) 17.7–51.9
PASE score (0–1100) 193.2 (90.2) 0.0–592.5
1,25(OH)2D, pg/mL 59.3 (16.5) 13.6–164.6
25(OH)D, ng/mL 24.4 (12.4) 2.0–84.4
PTH, pg/mL 28.4 (12.1) 1.1–96.8
Creatinine, mol/L 90.9 (16.5) 25.0–176.0
Calcium, mmol/L 2.4 (0.1) 1.2–3.3
T, nmol/L 16.4 (6.0) 0.2–46.8
Free T, pmol/L 288.9 (88.4) 1.5–695.1
E2, pmol/L 73.5 (24.7) 9.9–229.0
Free E2, pmol/L 1.3 (0.4) 0.1–4.3
SHBG, nmol/L 42.9 (19.8) 8.8–200.0
IGF-I, ng/mL 132.2 (43.1) 7.6–363.2
QUS
BUA, dB/MHz 80.4 (18.9) 6.3–201.7
SOS, m/s 1550.1 (34.2) 1458.7–1784.4
DXA
Total hip, g/cm2 1.018 (0.145) 0.4–1.4
Lumbar spine, g/cm2 1.066 (0.182) 0.5–1.6
Bone markers
P1NP, ng/mL 42.4 (20.8) 6.2–473.9
-cTX, pg/mL 360.6 (182.4) 10.0–1330.0
Current smokers 21.1%
Alcohol consumptiona 55.5%
Taking corticosteroids 3.6%
Taking vitamin D/calcium 0.6%
a More than 1 d/wk.
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persisted after adjustment for age and center, with no ev-
idence of threshold effects. When an interaction with
1,25(OH)2D was explored, the negative association be-
tween 25(OH)D and PTH was more marked in subjects in
the highest quintile of 1,25(OH)2D compared with those
in the lowest quintile ( for difference in slope  .140;
P  .007). Further adjustment for serum calcium levels
had no influence on the results.
Association between 1,25(OH)2D, 25(OH)D,
and PTH and age, anthropometric, lifestyle,
and hormonal factors
The association between 1,25(OH)2D, 25(OH)D, and
PTH and age, anthropometric, lifestyle, hormonal, and
biochemical factors are shown in Table 2. 1,25(OH)2D
decreased and PTH increased with age, but there was no
association between 25(OH)D and age. 1,25(OH)2D was
Figure 1. 1,25(OH)2D (A) and 25(OH)D (B) levels by month of measurement. Values are mean and 95% CI.
Figure 2. Association between 1,25(OH)2D and 25(OH)D (A), 25(OH)D and PTH (B), and 1,25(OH)2D and PTH (C). The solid lines represent the
linear relationship, and the dashed lines represent locally weighted scatterplot smoothing (LOWESS).
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associated with height. Body weight and BMI were posi-
tively associated with PTH and negatively associated with
both 1,25(OH)2D and 25(OH)D. Higher levels of physical
activity as measured by PASE score were positively associated
with 1,25(OH)2D and 25(OH)D, whereas poor physical per-
formance as measured by the time to walk 50 feet and also
smoking and no alcohol intake were negatively associated.
25(OH)D was positively associated with serum creatinine,
calcium, total T, free T, and IGF-I. 1,25(OH)2D was positively
associated with serum calcium and total T and negatively as-
sociated with creatinine, whereas PTH was positively associ-
ated with serum creatinine, total E2, and free E2 and negatively
associated with calcium, total T, SHBG, and IGF-I (Table 2).
Association between 1,25(OH)2D,25(OH)D, PTH,
and bone health parameters
After adjustment for age, center, height, weight, PASE
score, current smoking, alcohol consumption, and season
of measurement, higher levels of 1,25(OH)2D were asso-
ciated with higher levels of the bone resorption marker
-cTX (Table 3). 1,25(OH)2D did not appear to be related
to the bone formation marker P1NP. In contrast,
25(OH)D was not associated with markers of bone turn-
over. Higher levels of PTH were associated with higher
levels of both markers of bone turnover (Table 3).
Higher 1,25(OH)2D was associated with lower QUS
parameters at the heel and DXA BMDa at the lumbar spine
(Table 4). Similar results were observed for QUS BUA and
SOS, so only the results for SOS are presented here. When
categorized into quintiles, those in the highest (vs lowest)
quintile of 1,25(OH)2D had significantly lower SOS and
total hip and lumbar spine BMDa. However, higher
25(OH)D was associated with higher SOS at the heel and
DXA BMDa at the total hip and lumbar spine. There was
some inconsistency across the categories, although there
was no evidence of any threshold effects when 25(OH)D
was categorized into quintiles (Table 4). PTH was unre-
lated to the SOS, but higher PTH levels were associated
with lower BMDa at the total hip although not the lumbar
spine. Compared with those in the lowest quintile of PTH,
those in the fourth quintile had lower BMDa at both the
total hip and lumbar spine (Table 4). Further adjustment
for creatinine, serum calcium, and total T made no differ-
ence to the 1,25(OH)2D or 25(OH)D results (data not
shown), but further adjustment for serum creatinine, cal-
cium, and total T attenuated the associations between
PTH and hip and lumbar spine BMDa (data not shown).
When the subjects were categorized by both vitamin D
metabolite levels, those in the lowest tertile of 25(OH)D
Table 2. Association Between 1,25(OH)2D, 25(OH)D, PTH and Age, Anthropometry, Lifestyle, and Hormonal Factors
-Coefficient (95% CI)a
1,25(OH)2D (per SD) 25(OH)D (per SD) PTH (per SD)
Age (y)b .007 (.010, .004)c .000 (.003, .003) .014 (.011, .017)c
Height (cm) .012 (.017, .006)c .005 (.000, .011) .005 (.001, .010)
Weight (kg) .008 (.011, .006)c .004 (.007, .002)d .007 (.004, .010)c
BMI (kg/m2) .022 (.031, .013)c .020 (.029, .012)c .022 (.013, .031)c
PASE score (per 100) .110 (.062, .158)c .133 (.086, .180)c .040 (.089, .010)
Time to walk 50 feet (sec) .014 (.026, .002)e .027 (.039, .016)c .010 (.003, .022)
Current smoker (yes vs no) .172 (.262, .083)c .267 (.355, .179)c .081 (.172, .011)
Alcohol consumption/wk
None .189 (.308, .069)d .134 (.253, .016)e .010 (.113, .132)
1 day .047 (.153, .058) .063 (.168, .041) .060 (.048, .168)
1–2 days Referent Referent Referent
3–4 days .027 (.100, .155) .009 (.118, .136) .079 (.051, .210)
5–6 days .040 (.199, .119) .029 (.187, .128) .109 (.054, 0.271)
Every day .096 (.028, .219) .009 (.131, .114) .025 (.151, .102)
Creatinine (per SD) .120 (.159, .082)c .082 (.044, .121)c .086 (.046, .125)c
Calcium (per SD) .051 (.008, .094)e .086 (.043, .130)c .136 (.178, .093)c
Total T (per SD) .043 (.006, .079)e .054 (.018, .090)d .051 (.088, .013)d
Free T (per SD) .025 (.015, .065) .062 (.022, .101)d .015 (.056, .026)
Total E2 (per SD) .013 (.024, .049) .024 (.060, .012) .038 (.001, .075)
e
Free E2 (per SD) .009 (.046, .028) .039 (.075, .002)
e .073 (.036, .111)c
SHBG (per SD) .028 (.010, .067) .009 (.029, .047) .058 (.097, .019)d
IGF-I (per SD) .010 (.047, .028) .071 (.034, .108)c .054 (.092, .015)d
a Adjusted for age and center except where adjusted for center only.
b Adjusted for center.
c P  .001.
d P  .01.
e P  .05.
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and the highest tertile of 1,25(OH)2D had higher-cTX as
well as lower SOS at the heel and lower BMDa at the total
hip and lumbar spine compared with the subjects in the
middle to high tertiles of 25(OH)D and middle to low
tertiles of 1,25(OH)2D (Tables 3 and 4).
When the subjects were categorized by 25(OH)D and
PTH levels, those in the lowest tertile of 25(OH)D and the
highest tertile of PTH levels had higher bone turnover
markers and lower heel SOS, hip, and lumbar spine BMDa
compared with those in the middle to high tertiles of
25(OH)D and middle to low tertiles of PTH.
Excluding those on antiosteoporotic medication or
those receiving calcium/vitamin D supplementation made
no difference to any of the results.
Discussion
In this population-based sample of middle-aged and older
European men, 1,25(OH)2D was positively associated
with 25(OH)D but not with PTH. 25(OH)D was nega-
tively related to PTH. Both metabolites of vitamin D
showed similar seasonal variation. Higher 1,25(OH)2D
was associated with higher -cTX levels, lower QUS pa-
rameters at the heel, and lower DXA BMDa at the lumbar
spine. In contrast, higher 25(OH)D was not associated
with bone turnover but correlated significantly with
higher QUS parameters and DXA BMDa at the hip and
lumbar spine. Subjects in the lowest tertile of 25(OH)D
and the highest tertile of 1,25(OH)2D had the highest
-cTX and the lowest QUS and DXA BMDa values. PTH
was positively related to markers of bone turnover and
weakly negatively associated with BMDa at the hip. As
expected, subjects in the lowest tertile of 25(OH)D and the
highest tertile of PTH had higher bone turnover and lower
QUS and DXA BMDa.
We observed a significant but modest decline in
1,25(OH)2D, but not 25(OH)D, with age in keeping with
some (17–19) but not all studies (20, 21). This implies that
Table 3. Association of 1,25(OH)2D, 25(OH)D, and PTH with Bone Turnover
-Coefficient (95% CI)a
P1NP (per SD) -cTX (per SD)
1,25(OH)2D (per SD) .017 (.025, .058) .162 (.124, .201)
b
1,25(OH)2D quintiles
1: 45.6 Referent Referent
2: 45.6–54.0 .006 (.129, .116) .049 (.064, .163)
3: 54.1–61.7 .013 (.111, .138) .167 (.052, .282)c
4: 61.8–72.2 .089 (.037, .216) .288 (.170, .405)b
5: 72.2 .079 (.050, .209) .496 (.376, .615)b
25(OH)D (per SD) .039 (.084, .007) .029 (.071, .014)
25(OH)D quintiles
1: 14.1 Referent Referent
2: 14.1–19.4 .075 (.199, .048) .083 (.199, .033)
3: 19.5–25.3 .011 (.115, .138) .012 (.131, .107)
4: 25.4–33.7 .080 (.211, .051) .112 (.235, .011)
5: 33.7 .097 (.238, .044) .090 (.222, .043)
Vitamin D categories
Mid- or highest tertile 25(OH)D/mid- or lowest tertile 1,25(OH)2D Referent Referent
Mid- or highest tertile 25(OH)D/highest tertile 1,25(OH)2D .047 (.054, .148) .280 (.186, .374)
b
Lowest tertile 25(OH)D/mid- or lowest tertile 1,25(OH)2D .005 (.108, .099) .055 (.041, .151)
Lowest tertile 25(OH)D/highest tertile 1,25(OH)2D .114 (.057, .286) .453 (.294, .612)
b
PTH (per SD) .121 (.081, .160)b .196 (.159, .233)b
PTH quintiles
1: 18.84 Referent Referent
2: 18.84–23.89 .094 (.029, .216) .097 (.018, .211)
3: 23.90–29.11 .191 (.068, .314)c .222 (.107, .336)b
4: 29.12–36.31 .266 (.141, .392)b .316 (.199, .434)b
5: 36.31 .359 (.234, .485)b .527 (.410, .644)b
25(OH)D/PTH categories
Mid- or highest tertile 25(OH)D/mid- or lowest tertile PTH Referent Referent
Mid- or highest tertile 25(OH)D/highest tertile PTH .203 (.098, .308)b .276 (.178, .374)b
Lowest tertile 25(OH)D/mid- or lowest tertile PTH .053 (.163, .057) .076 (.179, .026)
Lowest tertile 25(OH)D/highest tertile PTH .181 (.057, .305)c .306 (.191, .422)b
Highest tertile of 1,25(OH)2D is greater than 64.6 pg/mL, lowest tertile of 25(OH)D is less than 17.7 ng/mL, and highest tertile of PTH is greater
than 31.20 pg/mL.
a Adjusted for age, center, height, weight, PASE score, current smoking, alcohol consumption, and season of measurement.
b P  .001.
c P  .01.
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renal capacity to synthesize 1,25(OH)2D, in addition to
25(OH)D production in the skin in response to sunlight,
may be relatively well conserved, even in elderly commu-
nity-dwelling men. Sunlight exposure, however, also ap-
peared to have an influence on serum 1,25(OH)2D as re-
flected by our observation of seasonal variation in
1,25(OH)2D levels very similar to that of 25(OH)D. Al-
though the seasonal variation of serum 25(OH)D levels is
well established (35, 36), the influence of season on
1,25(OH)2D has been a matter of debate in the literature
(18–20, 37), with some studies reporting seasonal differ-
ences in 25(OH)D-deficient subjects only (1, 37), which is
consistent with the endocrinological principles of negative
feedback. We observed seasonal variation in 1,25(OH)2D
at all levels of 25(OH)D, including in men who were
25(OH)D replete (data not shown).
In our study, as in others (17–19), 1,25(OH)2D was
positively associated with 25(OH)D, also in agreement
Table 4. Association of 1,25(OH)2D, 25(OH)D and PTH With QUS SOS and DXA-Assessed BMDa
-Coefficient (95% CI)a
QUS SOS
(per SD)
DXA Total Hip
BMDa (per SD)
DXA Lumbar Spine
BMDa (per SD)
1,25(OH)2D (per SD) .077 (.116, .038)
b .051 (.142, .041) .111 (.209, 0.013)d
1,25(OH)2D quintiles
1: 45.6 Referent Referent Referent
2: 45.6–54.0 .022 (.137, .094) .285 (.538, .032)d .213 (.483, .057)
3: 54.1–61.7 .047 (.163, .070) .154 (.407, .099) .175 (.444, .095)
4: 61.8–72.2 .080 (.199, .039) .123 (.394, .149) .138 (.429, .152)
5: 72.2 .212 (.333, .090)c .281 (.551, .011)d .403 (.692, .115)c
25(OH)D (per SD) .073 (.031, .116)c .164 (.078, .249)b .102 (.009, .194)d
25(OH)D quintiles
1: 14.1 Referent Referent Referent
2: 14.1–19.4 .046 (.071, .162) .071 (.374, .232) .064 (.391, .262)
3: 19.5–25.3 .112 (.007, .232) .211 (.087, .509) .303 (.019, .624)
4: 25.4–33.7 .099 (.024, .222) .244 (.061, .549) .180 (.147, .507)
5: 33.7 .159 (.026, .291)d .336 (.042, .630)d .258 (.058, .574)
Vitamin D categories
Mid- or highest tertile 25(OH)D/mid-
or lowest tertile 1,25(OH)2D
Referent Referent Referent
Mid- or highest tertile
25(OH)D/highest tertile
1,25(OH)2D
.156 (.251, .061)c .128 (.321, .065) .227 (.433, .021)d
Lowest tertile 25(OH)D/mid- or
lowest tertile 1,25(OH)2D
.126 (.223, .029)d .319 (.545, .094)c .255 (.496, .014)d
Lowest tertile 25(OH)D/highest
tertile 1,25(OH)2D
.375 (.536, .214)b .625 (1.050, .201)c .887 (1.340, .435)b
PTH (per SD) .023 (.061, .015) .098 (.184, .011)d .032 (.125, .061)
PTH quintiles
1: 18.84 Referent Referent Referent
2: 18.84–23.89 .046 (.164, .072) .091 (.358, .176) .071 (.358, .216)
3: 23.90–29.11 .006 (.112, .124) .262 (.526, .002) .026 (.310, .258)
4: 29.12–36.31 .044 (.164, .077) .366 (.634, .098)c .294 (.582, .007)d
5: 36.31 .066 (.186, .054) .230 (.504, .045) .085 (.380, .210)
25(OH)D/PTH categories
Mid- or highest tertile 25(OH)D/mid-
or lowest tertile PTH
Referent Referent Referent
Mid- or highest tertile
25(OH)D/highest tertile PTH
.024 (.125, .076) .054 (.255, .146) .085 (.300, .130)
Lowest tertile 25(OH)D/mid or
lowest tertile PTH
.096 (.201, .009) .252 (.515, .011) .251 (.534, .032)
Lowest tertile 25(OH)D/highest
tertile PTH
.148 (.266, .030)d .480 (.763, .198)c .404 (.708, .100)c
Highest tertile of 1,25(OH)2D is greater than 64.6 pg/mL, lowest tertile of 25(OH)D is less than 17.7 ng/mL, and highest tertile of PTH is greater
than 31.20 pg/mL.
a Adjusted for age, center, height, weight, PASE score, current smoking, alcohol consumption, and season of measurement.
b P  .001.
c P  .01.
d P  .05.
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with the substrate-dependent nature of 1,25(OH)2D syn-
thesis. However, only approximately 12% of the variation
of 1,25(OH)2D was explained by 25(OH)D, implying that
other factors such as diet (calcium and phosphate intake),
serum calcium and phosphate concentrations, immobility,
and renal function as well as genetic background may also
determine 1,25(OH)2D levels (12). We observed differ-
ences in the levels of both 1,25(OH)2D and, as previously
reported (38), 25(OH)D between European centers. These
differences were, however, not associated with latitude,
and no other specific patterns emerged, with some centers
having low 25(OH)D but high 1,25(OH)2D, whereas oth-
ers had both high 25(OH)D and 1,25(OH)2D, providing
further evidence that many factors determine vitamin D
status at a population level.
We found only a modest correlation between
1,25(OH)2D and PTH that was attenuated by adjustment
for other factors. Previous studies are also discordant,
with some finding an association (17, 18) and others not
(19). The mechanism for a lack of association is unclear,
however, because PTH is considered the major driver of
bone resorption in men with low 25(OH)D. The absence
of a strong 1,25(OH)2D-PTH relationship is interesting
because the rise of PTH in response to 25(OH)D is often
used to define a threshold of serum 25(OH)D. We ob-
served a relationship between 25(OH)D and PTH in keep-
ing with several studies (11, 39, 40).
This is the first study to examine the association between
1,25(OH)2D and bone turnover. Serum 1,25(OH)2D was
positively associated with the bone resorption marker
-cTX. This higher rate of bone turnover did not, however,
translate into lower QUS/DXA parameters across the phys-
iological range of 1,25(OH)2D: only the highest concentra-
tionsof1,25(OH)2D(above72pg/mL)wereassociatedwith
lower QUS/DXA parameters. These findings are consistent
with the notion that 1,25(OH)2D, in addition to its well-
established stimulatory effect on intestinal calcium absorp-
tion in response to calcium intake, may also increase bone
resorption. Indeed,recentdatafrominvitroandanimalstud-
ies suggest that 1,25(OH)2D may have a direct effect on os-
teoblasts and hence bone resorption because of its well-es-
tablished interaction with the receptor activator of nuclear
factor-B/receptor activator of nuclear factor-B ligand sig-
naling pathway (13, 14). The observation of an association
between 1,25(OH)2D and bone resorption in this cohort
may indeed reflect a physiological adaptive mechanism to
changes in calcium status, which appears independent of
PTH and leads to bone loss only in men with the highest
1,25(OH)2D levels. We did not observe an association be-
tween 25(OH)D and bone turnover, in contrast to a Dutch
study of older men and women (11). Although this was
slightly surprising, given the relationship between 25(OH)D
andPTH, it ispossible that thepreviouslyobservedthreshold
effect between 25(OH)D and bone turnover markers may
not apply to healthy middle-aged and older men.
Data on 1,25(OH)2D and bone health are scarce and
conflicting. A study of 62 healthy men aged 30–92 years
found no association between 1,25(OH)2D and radial or
vertebral bone mineral content (21). The Study of Osteo-
porotic Fractures Research Group provided evidence to
suggest that the risk of hip fracture increased by a factor
of 2.1 (95% CI 1.2–3.5) in postmenopausal women with
low serum 1,25(OH)2D [23 pg/mL (55 pmol/L)] (22);
however, these conclusions were based on a relatively
small nested case-control analysis using a Study of Os-
teoporotic Fractures subset of 133 women who subse-
quently had hip fractures. Another study, which in-
cluded men, found lower 1,25(OH)2D levels in hip
fracture patients compared to controls (23). In contrast,
the association we observed between 25(OH)D and
QUS/DXA parameters has been well documented (2–
11), although whether this reflects a causal relationship
or merely the fact that 25(OH)D is an excellent marker
of general health is still a matter for debate. Our ob-
servation of a lack of association between 25(OH)D and
markers of bone turnover is also in keeping with some
(6) but not all studies (11).
The influence of PTH on bone is well established (1, 41,
42). There are, however, few studies examining the rela-
tionship between PTH and bone turnover in men, but our
observation, which we have previously reported (34), of a
positive association is in accord with data from a study of
community-dwelling French men aged 55–85 years (6).
Our observation of a weak association with BMDa at the
hip is also concordant with some other community-based
studies of men (3, 5, 6, 42).
What are the implications of these data? These results
contribute to the understanding of the influence of
1,25(OH)2D on bone health in middle-aged and elderly
men. As far as we are aware, this is the first population-
based study to show that high levels of 1,25(OH)2D are
associated with poorer bone health. Men in the highest
tertile of 1,25(OH)2D and lowest tertile of 25(OH)D had
a lumbar spine BMDa almost 1 SD lower, which could
equate to a 2-fold increase in risk of fracture (43). A pos-
sible explanation for this is that low 25(OH)D (and con-
sequently poorer bone health) is being compensated for by
higher PTH, which in turn increases 1,25(OH)2D levels.
Our study has a number of advantages. It is large and
population based and used standardized methods in as-
sessment of QUS, DXA, vitamin D metabolites, PTH, and
lifestyle and other characteristics. In addition, we have
previously described a new, highly accurate LC-MS/MS
method for measuring 1,25(OH)2D (27) and in this study
J Clin Endocrinol Metab, March 2013, 98(3):995–1005 jcem.endojournals.org 1003
examine its performance in a community-based sample for
the first time. The addition of lithium salt conjugated fa-
vorably with 1,25(OH)2D, thus increasing its ability to be
ionized and measured by the mass spectrometer. This en-
abled accurate measurement of low concentrations of
1,25(OH)2D in a large number of samples using only 200
L of serum without the need for time-consuming
derivatization.
There are, however, a number of limitations to be con-
sidered when interpreting the results. The overall response
rate for participation was 45%. It is possible that those
invited but who did not take part may have differed with
respect to levels of the bone health measurements and vi-
tamin D/PTH than those who took part, and therefore, the
data concerning the absolute levels of these parameters
need to be interpreted with caution. Any factors influenc-
ing participation, however, are unlikely to have influenced
the results of the analysis, which was based on an internal
comparison of those who participated. This study, like
most epidemiological studies, was based on a single assay
of 1,25(OH)2D/25(OH)D and PTH levels. The epiforms
of 1,25(OH)2D could not be differentiated using our LC-
MS/MS method. Some measurement error for serum PTH
may have occurred despite the use of morning fasting sam-
ples that might not have fully corrected for the diurnal
variation of PTH (44). This would have tended to reduce
the chances of finding associations between 1,25(OH)2D/
25(OH)D, PTH, and BMDa rather than produce spurious
associations. We did not have accurate data on dietary
calcium, dietary/serum phosphate, or any other markers
of 1-hydroxylase activity, which could influence serum
1,25(OH)2D levels. Given the cross-sectional design of the
study, it is not possible to determine the temporal or causal
nature of the observed relationships. Finally, the study was
based on assessment of middle-aged and older European
men and extrapolation beyond this group should be un-
dertaken with caution.
In summary, in this population sample of middle-aged
and older European men, higher 1,25(OH)2D levels were
associated with higher bone turnover and poorer bone
health despite also being modestly associated with higher
25(OH)D. A combination of high 1,25(OH)2D and low
25(OH)D was associated with the poorest bone health.
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